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Abstract 10 
The immune contexture characterizes the clinical impact of the density, the location, 11 
the organization and the functional orientation of tumor-infiltrating immune cells in 12 
cancers. It is, in great part, shaped by the malignant cells, as in a given cancer type, 13 
tumors presenting different oncogenic processes have different immune contextures. 14 
Moreover, the immune contexture in metastatic sites reflects that of the corresponding 15 
primary tumors. Finally, the components forming the immune contexture represent 16 
targets and markers of efficient anti-cancer immunotherapies. 17 
 18 
Introduction 19 
Cancers grow and spread in tissues where the malignant cells interact with blood and 20 
lymphatic vessels, stromal cells and hematopoietic cells involved in immune and 21 
inflammatory reactions.  This landscape constitutes the immune contexture of a tumor 22 
which is of paramount importance for patients’ clinical outcome, is predictive of 23 
responses to therapies and helps identifying novel targets for immunotherapies [1]. 24 
 25 
Clinical impact of the immune contexture in different primary tumors 26 
 27 
The immune contexture is a concept that emerged from studies mostly performed in 28 
human colorectal cancer (CRC). A comprehensive analysis of a large collection of 29 
primary CRC tumors revealed that a high density of intratumoral memory T cells 30 
correlates with patients’ longer disease-free (DFS) and overall (OS) survivals [2], 31 
confirming a previous report in ovarian cancer [3]. A closer histopathological analysis 32 
of CRC tumors highlighted the fact that the T cells were not stochastically distributed 33 
within the tumor microenvironment but were present in the center (CT) and the 34 
invasive margin (IM) of the tumor nests [4]. The densities of memory CD8+ T cells in 35 
both the CT and the IM were associated with favorable prognosis, as well as the 36 
expression of genes encoding Th1 cytokines (IFN-γ, IL2) and cytotoxic mediators 37 
(granzymes, granulysin)[4]. A comprehensive approach of all genes having any type of 38 
correlation with genes whose expression correlated with both clinical outcome and 39 
tumor infiltration by T cells predicted that certain chemokines (CXCL13, CXCL9, 40 
CXCL10) were involved in shaping an efficient immune microenvironment [5] and 41 
foster T cells activation [6]. 42 
In parallel to these studies in CRC, our group has investigated the immune 43 
microenvironment of Non-Small-Cell-Lung Cancer (NSCLC). In addition to confirming 44 
the beneficial effect of high densities of T cells with a Th1 orientation and of cytotoxic 45 
CD8+ T cells, these studies revealed the essential role of tumor-associated Tertiary 46 
Lymphoid Structures (TLS), lymphoid aggregates that structurally resemble secondary 47 
lymphoid organs [7][8]. These formations are present in the invasive margin and in the 48 
3 
 
stroma of lung tumors and absent in distant non–tumoral lung tissue. They are 49 
organized in a T-cell and a B-cell zone surrounded by High Endothelial Venules (HEV). 50 
T cells are in contact with mature DC, and B cells with follicular dendritic cells (FDC) 51 
and tingible-body macrophages. B cells express the activation-induced deaminase 52 
(AID) enzyme necessary for somatic hypermutation and immunoglobulin isotype 53 
switching, a marker of active germinal center (GC) [9]. These data led us to hypothesize 54 
that TLS are sites where immune reactions toward tumor-associated antigens are 55 
generated [10]. Since they are exclusively present within TLS, naïve T and B cells may 56 
have emigrated from peripheral blood via HEV. Thus, TLS may represent an immune-57 
privileged site where naïve lymphocytes may be protected from the 58 
immunosuppressive and inflammatory milieu of the tumor during their differentiation 59 
phase. Indeed, high density of these tumor-associated TLS positively correlates with 60 
NSCLC patient’s prognosis [8][9][7]. This is in accordance with the fact that HEV are the 61 
only type of blood vessels which positively correlates with favorable clinical outcome of 62 
cancer [11]. TLS-infiltrating naive B cells differentiate into memory B cells and plasma 63 
cells which produce anti-tumor antibodies [9]. T cells in TLS are educated by antigen-64 
presenting DC, become memory lymphocytes and migrate into other tumor areas, 65 
resulting in local control, and to peripheral lymph nodes where they restrain metastatic 66 
spread[10]. TLS likely influence the functional orientation of tumor-infiltrating T cells, 67 
as intratumor T cells have a Th1 and cytotoxic CD8 orientation in tumors having high 68 
TLS densities [8].   69 
These initial observations in CRC and NSCLC have been extended to most cancer types 70 
[1][10]. Indeed the evaluation of the immune contexture involves quantitative 71 
immunohistochemistry and gene expression techniques (for evaluation of Th 72 
orientation for instance) and both type of assays needs expertise to be performed 73 
successfully. Regarding T cell infiltration, an “Immunoscore” has been defined 74 
quantifying by immunochemistry two out of the three markers, CD3, CD8 and CD45RO, 75 
in the invasive margin and the center of tumors[12]. A general trend emerges that high 76 
densities of memory T cells with a Th1 orientation and CD8+ phenotype correlate with 77 
longer DFS and OS also in ovarian, bladder, breast, prostatic, head and neck, and 78 
cervical cancers, hepatocellular carcinoma and melanoma (reviewed in [1] and [13]).  79 
Regarding TLS or Ectopic Lymphoid Structures, their quantification has been 80 
performed using the DC-Lamp marker, lymphoid aggregates in HES sections, CD20 81 
positive follicles or PNAd+ marker for HEV. Whatever the methodology used, the data 82 
show that high densities of TLS also correlate with favorable clinical outcome in CRC, 83 
breast, gastric, pancreatic, colorectal and renal cancers, oral squamous carcinoma, 84 
Merkel cell carcinoma, Warthin tumor as well as melanoma (reviewed in [10]). These 85 
studies establish the immune contexture as a well-studied, robust and clinically 86 
relevant characteristic of human cancers biology. 87 
However T and B lymphocytes, and TLS are far from being the only components of the 88 
immune and inflammatory microenvironment of tumors. The densities and 89 
organization of these other cell types also influence patient’s clinical outcome although 90 
with less significant power. Indeed the identification of some cell subpopulations such 91 
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as Treg[14] or MDSC can be hampered by the lack of consensus markers. Howewer, a 92 
trend emerges that high densities of myeloid cells, such as macrophages, MDSCs and 93 
mast cells, and particularly M2 macrophages are associated with poor 94 
prognosis[13][15][16][17][18]. NK cells infiltrating tumors can be anergic[19][20]. 95 
Extensive NK cells infiltration has nonetheless usually been associated  with favorable 96 
patient outcome[6][21][22][23]. 97 
Regarding the other T cell subsets, their impact may depend on the cancer type. It is the 98 
case for Th2, Treg or Th17  (reviewed in [1]). High densities of DC, TFH and B cells in TLS 99 
correlate with favorable prognosis[6]. In presence of low or no TLS, high densities of 100 
stromal B cells, CD8+ T cells and DC are associated with poor prognosis, and may 101 
support pro-tumoral inflammation and T cell anergy, underlining again the importance 102 
of the location of the immune cells in the tumor landscape  [8]. 103 
Despite the general agreement on the favorable prognostic value of the density of Th1 104 
and CD8+ T cells, discordant results have been reported in clear cell RCC (ccRCC) [24], 105 
Hodgkin lymphoma [25] or uveal melanoma [26]. Intrigued by these results, we 106 
recently analyzed a cohort of primary ccRCC and confirmed that high densities of CD8+ 107 
T cells in the IM correlated with shorter DFS and OS [27]. Even more intriguingly, high 108 
expression of the IFN-γ, TBX21, and granzyme-B genes were a highly significant marker 109 
of poor prognosis [27]. These results prompted us to study the immune contexture of 110 
ccRCC.  We found that there were few TLS in most ccRCC tumors [28][10]. Most CD8+ T 111 
cells presented an exhausted phenotype with concomitant expression of LAG3 and PD-112 
1, and tumor cells expressed PD-1 ligands [27]. Patients with tumors containing high 113 
densities of PD-1+ CD8+ T cells, and PD-L1 or PD-L2 expression by tumor cells had the 114 
worst prognosis. Strikingly, in most ccRCC tumors, immature DC-Lamp+ DC were found 115 
outside TLS, close to blood vessels (and not to HEV). It is therefore likely that these DC 116 
instructed incoming T cells in an inflammatory and immunosuppressed milieu 117 
resulting in an abortive immune response. The IFN- production by T cells has been 118 
reported to induce PD-L1 and/or PD-L2 on tumor cells [29], resulting in an exhaustion 119 
of the immune reaction. Indeed, in the few tumors with high densities of mature DC 120 
inside TLS, high CD8+ T cells density correlated with favorable prognosis, supporting 121 
the role of TLS in educating HEV-penetrating naive T cells to recognize tumor-122 
associated antigens and to control cancer aggressiveness [27]. These data suggest that 123 
certain tumor types may be characterized by a disrupted immune contexture, most 124 
likely governed by the malignant cells. 125 
 126 
Clinical impact of the immune contexture in metastatic sites 127 
It is intuitively thought that tumor progression is accompanied by tumor escape from 128 
the immune system [30][31]. If this escape linearly followed cancer progression, the 129 
immune contexture of metastatic sites should not impact clinical outcome. However, 130 
high densities of CD8+ T cells in hepatic and lung metastases of CRC correlate with 131 
longer OS [28], as in primary CRC [4]. Densities of infiltrating immune cells were shown 132 
to be correlated between the primary tumors and matched metastases[28]. These 133 
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findings both suggest that the malignant cells are prominent in shaping their immune 134 
microenvironments. This hypothesis is strengthened by the study of lung metastases of 135 
ccRCC. In contrast to lung metastases of CRC in which high TLS and CD8+ T cell 136 
densities correlate with favorable prognosis, lung metastases of ccRCC have few TLS, 137 
and high CD8+ T cell densities correlate with shorter OS, as in primary ccRCC[28]. In 138 
addition, transcriptomic analyses revealed a higher expression of genes involved in 139 
inflammation, immunosuppression and angiogenesis in lung metastases from ccRCC 140 
than in lung metastases from CRC, confirming differences in the functional orientations 141 
of these immune contextures[28]. 142 
Clinical impact of the immune contexture within a given cancer 143 
Whole genome transcriptomic analyses provide a novel way to classify subgroups in a 144 
given cancer type. These unsupervised approaches complement genomic classifications 145 
by identifying malignant cell subgroups with distinct functional traits. We undertook an 146 
analysis of the expression of immune genes and the concomitant immune cell 147 
infiltration in cohorts of various human cancers. To precisely analyze the immune 148 
contexture of large collections of human cancers, we established transcriptomic 149 
signatures based on the specific expression of genes in a given hematopoietic subset. 150 
We identified robust immune metagenes for lymphocytes (T and B cell subsets, NK, T, 151 
cytotoxic cells), myeloid cells (macrophages, monocytes, granulocytes, DC) as well as 152 
endothelial cells and fibroblasts (EB submitted). These signatures were validated in 153 
vitro in mixtures of hematopoietic and tumor cells and ex-vivo on CRC tumor sections. 154 
They were completed by analyses of genes expressed modulating immune functions 155 
(cytokines, chemokines, MHC class I) that sign the functional orientation of the immune 156 
microenvironments. We review herein our data in two cancers, prototypic for the 157 
clinical impacts of their immune contextures, CRC and ccRCC. 158 
Different molecular classifications have been proposed for CRC and merged in a four-159 
subgroups consensus classification [32]. It identifies a microsatellite-instability (MSI)-160 
enriched group with good prognosis, a mesenchymal subgroup with the worst 161 
prognosis, and KRAS mutated and canonical subgroups with intermediate prognosis. 162 
We applied the immune signatures to these classifications. We analyzed three cohorts 163 
of CRC including over 2000 patients and found that molecular subgoups had distinct 164 
immune signatures. The hypermutated MSI-enriched subgroup had the highest 165 
infiltration of T cells along with cytotoxic lymphocytes, followed by the mesenchymal 166 
subgroup which also presented with high lymphocytic infiltration in the context of high 167 
myeloid cell infiltration as well as extensive presence of endothelial cells and 168 
fibroblasts [33]. The two other groups of tumors had very poor expression of the 169 
immune gene signatures. These analyses show that the malignant cells can influence 170 
the density of immune and inflammatory cells in tumors. The hypermutated MSI-171 
enriched group had the highest expression of genes involved in T cell chemotaxis 172 
(CXCL9, CXCL10, CXCL16), T cell activation (IFN-, IL15), T cell inhibition (PD-L1, PD-173 
L2, CTLA-4, LAG3), and TLS formation (CXCL13). The mesenchymal subgroup had the 174 
highest expression of genes involved in myeloid cell chemotaxis (CCL2), angiogenesis 175 
(VEGF, PDGF), immunosuppression (TGF), and inflammation (CCL2, complement-176 
6 
 
related genes). The two immune low groups had also the lowest MHC Class I expression 177 
[33]. Taken together, these data support the concept that the MSI-tumors, which have 178 
defects in the DNA-repair enzymes, produce mutated neo-antigens that activate T cells, 179 
concurring to shape a favorable immune contexture. In contrast, the mesenchymal 180 
tumors, through a high production of angiogenic and inflammatory molecules shape a 181 
disrupted immune contexture where inflammation fuels tumor growth while T cells are 182 
attracted, but not properly educated towards tumor antigens, resulting in a poor 183 
clinical outcome. Finally, tumors from conventional precursors and with high activation 184 
of the Wnt pathway, down-regulate their MHC Class I molecules and escape the T cell 185 
attacks, which correlates with intermediate prognosis.  186 
We also analyzed the immune signatures in ccRCC primary tumors from metastatic 187 
patients treated with Sunitinib, a tyrosine kinase inhibitor. Unsupervised 188 
transcriptomic analyses identified four molecular subgroups [34]. Patients of two 189 
subgroups responded well to Sunitinib treatment, and consistently had longer 190 
Progression-Free Survival (PFS) and OS. The patients of the two other subgroups 191 
poorly responded to Sunitinib treatment, and had the worst prognosis. The analyses of 192 
the immune signatures revealed that the worst prognostic group had the highest 193 
infiltration with lymphoid cells in the context of a high myeloid cell infiltration. Genes 194 
involved in T cell chemotaxis (CXCL9, CXCL10, CXCL13), Th1 orientation (IFN-, IL12, 195 
TBX21), T cell exhaustion (PD1, PD-L1, LAG3) and inflammation (TNF-α, CSF1) were 196 
highly expressed. The other bad prognosis group had the highest NK cell infiltration 197 
and the lowest expression of genes related to adaptive immunity including MHC Class I 198 
[32]. 199 
Altogether, this analysis of two prototypic tumors showed that within each cancer type, 200 
an immunological classification identifies different subtypes of patients with different 201 
clinical outcomes corresponding to different oncogenic processes. Thus, we already 202 
identified three cancer types  (Fig 1): 203 
 the “immunogenic tumors” with production of immunogenic peptides, and an 204 
organized immune contexture that generates anti-tumor T cells and antibodies, 205 
resulting in a favorable prognosis, 206 
 the “inflammatory tumors” with production of inflammatory, angiogenic and 207 
immunosuppressive molecules that disrupt the immune contexture and attract 208 
pro-tumor myeloid and lymphoid cells, resulting in exhausted tumor 209 
aggressiveness and poor patient’s clinical outcome, 210 
 the “escaping tumors” which down regulate their antigen-presenting machinery 211 
produce little or no chemokines and cytokines, and are blind to the immune 212 
attack. Patients with such tumors have an intermediate prognosis. 213 
These classifications not only reveal pathological features of cancers but also offer 214 
targets and predictive markers for immunotherapies (Table 1). 215 
The immune contexture and response to therapy 216 
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The immune microenvironment of tumors not only reflects the oncogenic processes of 217 
a cancer in a patient, but is also a constitutive arm of cancer control and thus of 218 
patient’s clinical outcome. It is therefore likely that therapeutic interventions modifying 219 
the immune contexture will result in profound changes in cancer evolution. 220 
Characterizing the immune contexture or the corresponding molecular profile of a 221 
tumor in a patient will allow clinicians to propose the most appropriate therapies. For 222 
instance, MSI CRC tumors with high mutational load respond to PD1 axis blockade [35]. 223 
Consistent results have been observed in NSCLC [36]. In melanoma patients treated 224 
with anti-PD-1 antibodies, responding tumors are characterized by the entry of pre-225 
existing CD8+ T cells from the IM to the CT[37], exemplifying the role of T cell location 226 
into tumors[4]. In cervical carcinoma [38] or pancreatic cancer [39], responses to 227 
therapeutic vaccination are accompanied by the increase of TLS in the tumor vicinity. 228 
In ccRCC patients responding to anti-PD-1 or anti-PD-L1 antibodies, tumors express 229 
both molecules on their infiltrating lymphocytes and tumor cells, respectively [40]. In 230 
bladder cancer, the expression of PD-L1 on infiltrating immune cells was found 231 
essential for response to this immunotherapy [41]. 232 
For immune silent tumors, bi-specific antibodies direct to tumor antigens may attract 233 
and activate T cells into responding tumors[42]. T cells-based therapies aim also to 234 
bring missing memory T cells into tumors. Strikingly, therapies with antibodies 235 
recognizing tumor-associated antigens, such as CD20 [43], or HER2-Neu [44], are 236 
capable of inducing a memory anti-tumor T cell response responsible for the long-term 237 
effect of these therapies. In tumors where class I MHC molecules are downregulated, 238 
autologous NK cells transfer, recombinant IL15 or KIR-blocking antibodies could foster 239 
NK cells activation and MHC-negative tumor cells elimination[45]. Finally, the immune 240 
microenvironment is implicated in the long lasting effects of chemotherapies and 241 
radiotherapies, by creating an appropriate microenvironment associated with the 242 
release of immunogenic molecules by the tumor cells. 243 
 244 
 245 
 246 
 247 
  248 
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 421 
Figure 1. 422 
The immunological wheel. Cartoon depicting the three immune contextures than can 423 
be induced in tumors. The ‘immunogenic tumors’ are characterized by abundant 424 
Cytotoxic T-Lymphocyte (CTL) infiltration, the presence of Tertiary Lymphoid 425 
Structures (TLS) and low/moderate vascularization while associated with the longest 426 
patient’s survival. The ‘immune neglected’ tumors are characterized by lack of 427 
infiltration by immune cells, low/moderate vascularization and intermediate 428 
prognosis. Finally, the ‘inflammatory tumors’ are characterized by abundant CTL in the 429 
absence of TLS, conspicuous infiltration with M2 macrophages, severe vascularization 430 
and poor prognosis.  431 
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Immune 
subgroup 
Examples of 
corresponding 
molecular 
subgroups 
Microenvironment 
characteristics 
Escape 
mechanisms 
Immunotherapeutic 
goals 
Potential 
immunotherapeutic 
approach 
Immunogenic 
CRC  
Hypermutated 
High T cell 
infiltration 
with Th1 
orientation 
and cytotoxic 
lymphocytes 
Immune 
checkpoints : 
PD1 axis, 
LAG3, CTLA4 
Boost intratumor 
cytotoxic T cells 
Checkpoint-blockade 
Inflammatory 
CRC 
Mesenchymal 
 
ccrcc4 
High lymphocyte 
and myeloid cells 
infiltration 
High angiogenesis 
Stromal 
mesenchymal cells 
Hypoxia 
TGFß 
PD1 axis 
Dampen inflammation 
and associated 
suppressive 
mechanisms 
Establish normoxia 
Boost intratumor 
suppressed cytotoxic T 
cells 
Anti-angiogenic 
Anti TGFβ 
Checkpoint-blockade 
Immune 
neglected 
CRC Canonical 
and Metabolic 
 
ccrcc1 and 
ccrcc2 
Low lymphocytic 
and myeloid cells 
infiltration 
Low class I 
MHC 
expression 
Attract cytotoxic T 
cells in tumors 
Bypass class I MHC 
presentation 
CAR T cells 
Bi-specific antibodies 
 433 
Table 1. 434 
Immunotherapeutic approaches tailored for tumor immune subgroups. 435 
The three immune subgroups, their hallmarks, immune escape mechanisms are listed, 436 
as well as the corresponding immunotherapeutic goals and potential approaches. 437 
CRC : Colorectal cancer 438 
ccrcc : clear-cell Renal Cell Carcinoma 439 
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